Today, companies including Religare Enterprises, Gland Pharma, Fortis Malar Hospitals, Aditya Birla Capital, Alembic Pharma, ...

FM’s intent to give relief to patients will be realised more with GST exemption and will make a huge impact, considering that in India 80% of healthcare expenses are out of pocket, writes Biocon ...

Biocon Biologics CEO discusses revenue growth, market diversification, debt strategy, and impact of US pro-localisation policy.

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

Here’s a quick look at stocks likely to be in focus in today's trade. Bank of Baroda: Bank of Baroda posted a 5.6 percent ...

Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told ...

The drug discovery services market is expanding, driven by advancements in biotechnology, personalized medicine, and the increasing demand for efficient, cost-effective drug development solutions.” - ...

Adjusting for these one-time factors, operating revenue of Biocon grew 10% YoY to ₹3,821 crore, with total revenue increasing ...

The Competition Commission of India (CCI) recently imposed a penalty of Rs40 lakh on Goldman Sachs (India) Alternative ...

Paradeep Phosphates has signed a memorandum of understanding with the Odisha government for an investment of Rs 4,000 crore, ...

Stocks including L&T, JSW Steel, Wipro, Bank of Baroda, Biocon, Torrent Power, PB Fintech, Kalyan Jewellers and more will be ...

Biocon Ltd.'s disappointing Q3FY25 performance was largely due to exceptional items, with adjusted net profit standing at Rs 13 crore, and revenue growth of 7% on a like-for-like basis.